Compare Rocket Companies Inc. Class A Common Stock (RKT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Companies Inc. Class A Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Rocket Companies Inc. Class A Common Stock trades at $10.57 (market cap $30.67B), while Recursion Pharmaceuticals Inc trades at $3.66 (market cap $2.08B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 14.7× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Rocket Companies Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Companies Inc. Class A Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RKT | RXRX | |
|---|---|---|
Market Cap | $30.67B | $2.08B |
Volume | 41,104,143 | 19,700,033 |
Sector | Financials | Health |
52-Week High | $23.44 | $6.79 |
52-Week Low | $10.53 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $60.66B | $1.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
